– InsightRX raises $10M led by HealthX Ventures to accelerate the adoption of its precision dosing at the point of care platform.
– The platform leverages patient-specific data, pharmacology models, and machine learning to understand each patient’s unique pharmacological profile to guide treatment decisions.
– InsightRX plans to use the new funding to deepen its integration capabilities, broaden development across additional therapeutic areas, and continue its expansion into health systems and life science companies.
InsightRX, a San Francisco, CA-based healthcare technology startup dedicated to helping clinicians individualize medication dosing at the point of care announced today it has raised $10 million in Series A funding. The funding was led by HealthX Ventures, with participation from Rock Health, OSF Healthcare, Leawood Venture Capital, Premier Inc., and earlier investor GreatPoint Ventures. The latest round brings the company’s total funding to date at $13M.
Accelerating Adoption of Precision Dosing Nationwide
Founded in 2015 by Ron Keizer, Sirj Goswami, and Ranvir Mangat, InsightRX has created an integrated clinical decision support platform that individualizes treatment at the point of care. InsightRX leverages patient-specific data and pharmacology models to understand patients’ unique pharmacological profiles and, ultimately, determine appropriate dosing regimens.
The company’s cloud-based precision dosing platform, InsightRX Nova©, seamlessly integrates with hospital electronic health record (EHR) systems and enables clinicians to individualize medication dosing regimens at the bedside. InsightRX leverages patient-specific data, quantitative pharmacology models, and Bayesian forecasting to understand each patient’s pharmacological profile to guide treatment decisions. The quantitative pharmacology models are continuously improved over time using real-world clinical data and human-assisted artificial intelligence processes that leverage the team’s deep pharmacology expertise and various machine learning and modeling techniques. Currently, InsightRX Nova optimizes treatment across more than 100 drug and therapeutic areas, including oncology and infectious disease.
Clinical Analytics in Real-Time
Additionally, with the aggregated analytics provided by InsightRX Apollo, hospitals and care teams are able to improve treatment responses and discover novel factors that impact drug efficacy and toxicity. The Nova and Apollo platforms are used by more than a hundred healthcare institutions and life science companies throughout the US and Europe.
InsightRX also partners with leading biopharma companies to develop drug-specific companion applications for use in clinical trials. The ultimate goal is to include the IRX companion application as part of the drug label, accelerating the adoption of precision dosing on a global scale.
InsightRX plans to use the new funding to deepen its integration capabilities, broaden development across additional therapeutic areas, and continue its expansion into health systems and life science companies. This past March, InsightRX partnered with the Children’s Hospital Los Angeles (CHLA) to bring precision dosing to clinicians, with the company incorporating CHLA’s technology into its Nova platform.
“Precision dosing allows us to best achieve optimal therapeutic targets for each patient. This is especially important for many medications used in hospitalized infants and children who have highly variable concentrations after standard dosing—concentrations often below or above what is considered safe and effective,” said Dr. Michael Neely, Chief of Infectious Disease at CHLA. “As such, it is important to account for individual patient characteristics to maximize the chances of treatment success while minimizing toxicity.”
Why It Matters
“The future of healthcare relies on individualizing therapy and improving patient outcomes by providing clinicians with tools to make better treatment decisions,” said Sirj Goswami, co-founder and CEO of InsightRX. “Our platform individualizes dosing at the point of care and establishes a data-driven framework to continuously learn about treatment effectiveness—and the underlying factors influencing drug response.”